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WHY COMBINE TARGETED AGENTS?: While a number of tar-
geted agents have demonstrated clinical proof of principle as can-
cer therapeutics, the clinical benefits conferred by these targeted
agents are still limited, except in few circumstances where the
tumour pathogenesis is dominated by a single molecular abnor-
mality. Reasons for resistance to or escape from targeted agents
can be multiple, including absence or biological irrelevance of
the intended targets, redundant tumour growth and survival
pathways, or heterogeneity of tumour subclones. Optimization
of the therapeutic strategies should therefore include identifica-
tion of predictive markers for individualized selection of thera-
pies, and combination of targeted agents to simultaneously
block the multiple molecular pathways. Discussions in this ses-
sion were focused on strategies to overcome a host of intellectual
property, regulatory, and scientific challenges in the development
of regimens containing multiple targeted agents.1
INTELLECTUAL PROPERTY CHALLENGES: Combining targeted
agents when they are still investigational presents special chal-
lenges concerning intellectual property (IP), since individual
agents of interest are commonly under development by different
industry sponsors. Broad experience exists at the Cancer Treat-
ment Evaluation Program (CTEP) at the National Cancer Institute
(NCI) in the United States in sponsoring combination studies.
With access to more than a hundred investigational agents
through collaborative agreements with industry partners, CTEP
is uniquely positioned to provide a common platform to facilitate
studies combining two or more investigational agents. To encour-
age sponsors to provide proprietary agents for combination stud-
ies, CTEP has developed common intellectual property language,
which stipulates the option for each collaborator to receive non-
exclusive, royalty-free licenses to the combination IP for all pur-
poses including that of commercial use. (The template language
is available on the CTEP Website at http://CTEP.cancer.gov/indus-
try/ipo.html).
This template language has been well accepted by collabora-
tors and investigators. Under such agreements CTEP has spon-
sored >100 clinical trials and executed >60 preclinical materials
transfer agreements (MTAs) for studying combinations between
investigational agents.
REGULATORY ISSUES: Based on experience as sponsor of clini-
cal studies, preclinical toxicology for a combination regimen is
usually not required if adequate safety information in patients
are available for the individual agents. For approval of two exper-
imental agents in combination, it would probably be necessary to
demonstrate the contribution of each component of a fixed com-
bination regimen. Such evidence could generally be obtained in
clinical studies or form compelling preclinical data on the value
of combination and absence of activity with single agent.
GENERAL CONSIDERATIONS FOR CLINICAL EVALUATION OF
TARGET AGENT COMBINATIONS: Given the number of targeted
agents and almost limitless possibilities of combinations, a strat-
egy of prioritization would clearly be necessary.
Priority can be established based on the rationale of the tar-
gets, the credentials of the agent, and the strength of the preclin-
ical data for the combination. The primary target should be
relevant to the tumour being treated. The second target of the
combination regimen may be selected to (1) maximize inhibition
of the same signal (e.g., targeting both vascular endothelial
growth factor [VEGF] and its receptor), (2) maximize inhibition
of a pathway through inhibition of vertical targets (e.g., HER-2
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and mTOR), (3) block parallel pathways and cellular processes
(e.g., VEGF and epidermal growth factor receptor [EGFR]) or (4)
overcome the resistance mechanisms to the first agent.
When it comes to selecting the agents for the targets of inter-
est, the most important factor would be the credentials of the
agents, which should be based on either clinical evidence of antit-
umour activity or demonstrated of effects on the intended targets
in patients. It is also preferable to select agents with minimal
pharmacokinetic interactions and few, if any, overlapping toxici-
ties. Consistent evidence of synergism or additivity in preclinical
studies is also important in considering a combination regimen
for clinical testing, especially if one or both of the agents or tar-
gets have not yet been clinically validated.
CURRENT EXPERIENCE WITH CLINICAL EVALUATION OF
TARGETED AGENT COMBINATIONS: Several clinical trials for
combination between targeted agents ongoing (Table 1). Among
them is a multi-arm randomized phase II trial of several target
agent combinations (bevacizumab + sorafenib, bev-
acizumab + CCI-779, and CCI-779 + sorafenib) in patients with
renal cell carcinoma, with the purpose to select the promising
combinations for further evaluations. In the attempts to explore
biomarkers predictive of clinical outcome, the study will also
incorporate central banking of the tissue and blood samples as
well as performance of contract-enhanced dynamic MRIs.
While clinical experience with target agent combination is still
limited, some preliminary safety and efficacy data are available
and could provide insight to further development of this strategy.
A phase I study of combination between the VEGF neutralizing
antibody bevacizumab (Avastin) and the VEGF-receptor inhibitor
sorafenib (Nexavar) was performed. As expected, toxicities
related to inhibition of the VEGF target were exacerbated. At the
first dose level (bevacizumab 5 mg/kg every two weeks and
sorafenib 200 mg BID), which represented half of the single agent
Phase II doses, the combination regimen was barely tolerable and
required introduction of drug holidays.2,3 Toxicities such as pro-
teinuria, hypertension, and hand-foot syndrome occurred at ear-
lier onset and with higher severity than expected with the single
agents. Similarly, for combination between sorafenib and temsi-
rolimus (an mTOR inhibitor) or erlotinib and temsirolimus, dose
reductions were required when the agents were used in combina-
tion. On the other hand, combinations of agents with non-over-
lapping toxicities (e.g. bevacizumab plus erlotinib or cetuximab)
were well tolerated at full phase II doses of the single agents.4
There are as yet limited data to confirm the benefits that may
be derived from combination of targeted agents. Initial efficacy
assessments of anti-tumor activity have yielded mixed results.
For example, the first report of a phase 2 clinical trial assessing
the combination of gefitinib with trastuzumab in patients with
metastatic breast cancer did not identify a favorable interaction
between the agents.5 Similarly, while initial results from an
uncontrolled clinical trial suggested promising response data
for the combination of bevacizumab with erlotinib in renal cell
cancer,6 the subsequent randomized Phase 2 trial failed to dem-
onstrate improvement in objective response rate or progression
free survival compared to bevacizumab alone.7 On the other
hand, preliminary results for the combination of bevacizumab
and the EGFR targeting antibody cetuximab in colorectal cancer
(CRC) were promising, with the response rate and the progression
free survival endpoints both exceeding the historical data for
cetuximab alone.4 A confirmatory phase III trial for the addition
of cetuximab to bevacizumab and chemotherapy is now ongoing.
In addition, the phase I trials with bevacizumab and sorafenib
indicated promising activity in renal cell cancer and ovarian can-
cers,2,3 although phase II evaluations in these indications are still
pending.
SCIENTIFIC HURDLES FOR COMBINATION THERAPIES: Several
barriers to effective clinical testing of target agent combina-
tions can be identified, and they are fundamentally related
to our limited understanding of the agents mechanisms of
actions, the patient selection criteria and the optimal doses
and schedules of the drug administrations. Furthermore, the
clinical success or failure of combinations that have been
evaluated to date has not been clearly predicted by published
preclinical data. For example, the clinical results with gefitinib
plus trastuzumab in breast cancer or bevacizumab plus erloti-
nib in RCC were negative despite published preclinical evi-
dence for synergistic or additive activities of the
combinations. It was also recognized that in preclinical stud-
Table 1 – Combination of targeted/novel agents in clinical trials
Targets Clinical trial Tumour types
Block parallel pathways VEGR + EGFR Bevacizumab + cetuximab Colon, Pancreatic
Bevacizumab + erlotinib Breast, SCCHN, RCC, etc.
VEGF + PDGF/c-kit Bevacizumab + imatinib Melanoma, GIST
HER-2 + HER-1 Trastuzumab + gefitinib Breast
Maximize inhibition of one target VEGF + VEGFR/raf Bevacizumab + sorafenib RCC
EGFR + EGFR TKI C225 + erlotinib Colon
Vertical inhibition of pathway VEGF + mTOR Bevacizumab + temsirolimus RCC
HER-2 + mTOR Trastuzumab + everolimus Breast
EGFR + mTOR EGFR TKI + temsirolimus NSCLC, Glioma
HER-2 + CDK Trastuzumab + flavopiridol Breast
Modulating multiple biological processes HDAC + VEGF SAHA + bevacizuamb RCC
Vaccine + modulator Vaccine + anti-CTLA4 antibody Melanoma, Prostate
VEGF, PDGF, VEGFR, c-kit Bevacizumab + sunitinib RCC
SCCHN, squamous cell carcinoma of the head and neck; RCC, renal cell carcinoma; TKI, tyrosine kinase inhibitor.
E J C S U P P L E M E N T S 5 ( 2 0 0 7 ) 4 6 –5 2 49
ies a same combination could demonstrate synergism or
antagonism across different model systems.
The variable results of the same combination across different
tumour models is reflective of the heterogeneity of cancers,
pointing to the importance of patient selection. However, most
targeted agents were developed in unselected patients and the
activities were defined by the population average, often without
knowledge of the predictive markers. For combination regimens
with more than one targeted agent, the lack of patient selection
would not only compromise the efficiency of the clinical studies
but also make the outcome data misleading. For example,
improved efficacy of a combination may not be detectable in
the overall patient population if synergism is dependent on a spe-
cific molecular context that is only present in a small subset of
patients. Conversely, an improvement in the overall response rate
or progression free survival may not necessarily mean benefit of
the combination in individual patient, as the results may simply
reflect the summation of the outcomes of individual components
in different subsets of patients.
Also at issue is the limited guidance for optimal doses for the
combination regimens. Specifically, if dose reduction of individ-
ual agents is required for combination therapies due to safety
issues, would the combination still perform better than single
agents at full dose? In addition, it is possible to differentially
reduce the doses of the two agents and multiple MTDs may be
defined for the same combination. It is however difficult to deter-
mine which dose ratio would be optimal.
In addition the sequence of agent administrations is often
critical to the outcome of the combination, given the unique
mechanisms of actions of targeted agents. Indeed synergism of
many combination regimens has been found to be sequence-
dependent. However, not uncommonly, different tumour models
may produce conflicting results regarding the optimal sequence
for the same combination. Without knowledge of the molecular
contexts and clinical relevance of the preclinical models, it is dif-
ficult to apply these observations to clinical studies.
IMPROVING PRECLINICAL STUDIES: Clearly, more and better
preclinical and nonclinical studies are needed for overcoming
these barriers. Such non-clinical studies have the potential to
enhance our knowledge of the individual agents and their
combination, the mechanisms of actions, and markers for
responsiveness or resistance, all of which critical to optimiz-
ing the strategy for clinical development of combination regi-
mens. Nevertheless, the limitations of preclinical studies must
also be appreciated in order to appropriately use the model
systems.
Some ideas to improve preclinical studies were offered. A sys-
tematic effort is needed to molecularly characterize the human
tumours and preclinical models. Experiments for specific combi-
nations should be carried out in multiple tumour models and
include clinically relevant doses and exposures. The single-agent
control should be based on the full dose for comparison with the
combination regimen. More importantly, results should be inter-
preted in the molecular context of the models to maximize trans-
latability to the clinical settings.
One also cannot overemphasise the importance of correlative
studies for the search of predictive and pharmacodynamic mark-
ers. These correlative studies are not only important in clinical
trials but should start from non clinical studies, including those
on cell lines and animal models.
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INTRODUCTION: Cancer vaccines present unique developmen-
tal challenges. Some potential solutions exist, but they are not
widely known nor is there any consensus about their use. The
Cancer Vaccine Clinical Trial Working Group (CVCTWG), a joint
initiative of the Cancer Vaccine Consortium (CVC) and the inter-
national society for biological therapy of cancer (iSBTc), has pro-
posed a new clinical development paradigm for cancer vaccines
and immunotherapies through workshops conducted between
October 2004 and November 2005.
The goal of CTCVWG was to use collective knowledge in the
field to synthesize a flexible and applicable paradigm, reach a
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